FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2142118082> ?p ?o ?g. }

• W2142118082 endingPage "e67188" @default.
• W2142118082 startingPage "e67188" @default.
• W2142118082 abstract "Objectives South Africa’s national antiretroviral (ARV) treatment program expanded in 2010 to include the nucleoside reverse transcriptase (RT) inhibitors (NRTI) tenofovir (TDF) for adults and abacavir (ABC) for children. We investigated the associated changes in genotypic drug resistance patterns in patients with first-line ARV treatment failure since the introduction of these drugs, and protease inhibitor (PI) resistance patterns in patients who received ritonavir-boosted lopinavir (LPV/r)-containing therapy. Methods We analysed ARV treatment histories and HIV-1 RT and protease mutations in plasma samples submitted to the Tygerberg Academic Hospital National Health Service Laboratory. Results Between 2006 and 2012, 1,667 plasma samples from 1,416 ARV-treated patients, including 588 children and infants, were submitted for genotypic resistance testing. Compared with 720 recipients of a d4T or AZT-containing first-line regimen, the 153 recipients of a TDF-containing first-line regimen were more likely to have the RT mutations K65R (46% vs 4.0%; p<0.001), Y115F (10% vs. 0.6%; p<0.001), L74VI (8.5% vs. 1.8%; p<0.001), and K70EGQ (7.8% vs. 0.4%) and recipients of an ABC-containing first-line regimen were more likely to have K65R (17% vs 4.0%; p<0.001), Y115F (30% vs 0.6%; p<0.001), and L74VI (56% vs 1.8%; p<0.001). Among the 490 LPV/r recipients, 55 (11%) had ≥1 LPV-resistance mutations including 45 (9.6%) with intermediate or high-level LPV resistance. Low (20 patients) and intermediate (3 patients) darunavir (DRV) cross resistance was present in 23 (4.6%) patients. Conclusions Among patients experiencing virological failure on a first-line regimen containing two NRTI plus one NNRTI, the use of TDF in adults and ABC in children was associated with an increase in four major non- thymidine analogue mutations. In a minority of patients, LPV/r-use was associated with intermediate or high-level LPV resistance with predominantly low-level DRV cross-resistance." @default.
• W2142118082 created "2016-06-24" @default.
• W2142118082 creator A5006120211 @default.
• W2142118082 creator A5011012168 @default.
• W2142118082 creator A5020926690 @default.
• W2142118082 creator A5049454179 @default.
• W2142118082 creator A5050560272 @default.
• W2142118082 creator A5066628402 @default.
• W2142118082 creator A5069179698 @default.
• W2142118082 creator A5078825398 @default.
• W2142118082 creator A5089704709 @default.
• W2142118082 date "2013-06-26" @default.
• W2142118082 modified "2023-09-26" @default.
• W2142118082 title "Trends in Genotypic HIV-1 Antiretroviral Resistance between 2006 and 2012 in South African Patients Receiving First- and Second-Line Antiretroviral Treatment Regimens" @default.
• W2142118082 cites W2002163141 @default.
• W2142118082 cites W2008088525 @default.
• W2142118082 cites W2014490323 @default.
• W2142118082 cites W2045781352 @default.
• W2142118082 cites W2053320932 @default.
• W2142118082 cites W2105064834 @default.
• W2142118082 cites W2106026141 @default.
• W2142118082 cites W2114793603 @default.
• W2142118082 cites W2157702265 @default.
• W2142118082 cites W2161439171 @default.
• W2142118082 cites W2330682237 @default.
• W2142118082 doi "https://doi.org/10.1371/journal.pone.0067188" @default.
• W2142118082 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3694021" @default.
• W2142118082 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23840622" @default.
• W2142118082 hasPublicationYear "2013" @default.
• W2142118082 type Work @default.
• W2142118082 sameAs 2142118082 @default.
• W2142118082 citedByCount "60" @default.
• W2142118082 countsByYear W21421180822013 @default.
• W2142118082 countsByYear W21421180822014 @default.
• W2142118082 countsByYear W21421180822015 @default.
• W2142118082 countsByYear W21421180822016 @default.
• W2142118082 countsByYear W21421180822017 @default.
• W2142118082 countsByYear W21421180822018 @default.
• W2142118082 countsByYear W21421180822019 @default.
• W2142118082 countsByYear W21421180822020 @default.
• W2142118082 countsByYear W21421180822021 @default.
• W2142118082 countsByYear W21421180822022 @default.
• W2142118082 countsByYear W21421180822023 @default.
• W2142118082 crossrefType "journal-article" @default.
• W2142118082 hasAuthorship W2142118082A5006120211 @default.
• W2142118082 hasAuthorship W2142118082A5011012168 @default.
• W2142118082 hasAuthorship W2142118082A5020926690 @default.
• W2142118082 hasAuthorship W2142118082A5049454179 @default.
• W2142118082 hasAuthorship W2142118082A5050560272 @default.
• W2142118082 hasAuthorship W2142118082A5066628402 @default.
• W2142118082 hasAuthorship W2142118082A5069179698 @default.
• W2142118082 hasAuthorship W2142118082A5078825398 @default.
• W2142118082 hasAuthorship W2142118082A5089704709 @default.
• W2142118082 hasBestOaLocation W21421180821 @default.
• W2142118082 hasConcept C104317684 @default.
• W2142118082 hasConcept C114851261 @default.
• W2142118082 hasConcept C126322002 @default.
• W2142118082 hasConcept C135763542 @default.
• W2142118082 hasConcept C142462285 @default.
• W2142118082 hasConcept C156719811 @default.
• W2142118082 hasConcept C159047783 @default.
• W2142118082 hasConcept C182707283 @default.
• W2142118082 hasConcept C2777182164 @default.
• W2142118082 hasConcept C2779298103 @default.
• W2142118082 hasConcept C2779465607 @default.
• W2142118082 hasConcept C2781143361 @default.
• W2142118082 hasConcept C2781413609 @default.
• W2142118082 hasConcept C2993143319 @default.
• W2142118082 hasConcept C3013748606 @default.
• W2142118082 hasConcept C49105822 @default.
• W2142118082 hasConcept C54355233 @default.
• W2142118082 hasConcept C71924100 @default.
• W2142118082 hasConcept C86803240 @default.
• W2142118082 hasConcept C90924648 @default.
• W2142118082 hasConceptScore W2142118082C104317684 @default.
• W2142118082 hasConceptScore W2142118082C114851261 @default.
• W2142118082 hasConceptScore W2142118082C126322002 @default.
• W2142118082 hasConceptScore W2142118082C135763542 @default.
• W2142118082 hasConceptScore W2142118082C142462285 @default.
• W2142118082 hasConceptScore W2142118082C156719811 @default.
• W2142118082 hasConceptScore W2142118082C159047783 @default.
• W2142118082 hasConceptScore W2142118082C182707283 @default.
• W2142118082 hasConceptScore W2142118082C2777182164 @default.
• W2142118082 hasConceptScore W2142118082C2779298103 @default.
• W2142118082 hasConceptScore W2142118082C2779465607 @default.
• W2142118082 hasConceptScore W2142118082C2781143361 @default.
• W2142118082 hasConceptScore W2142118082C2781413609 @default.
• W2142118082 hasConceptScore W2142118082C2993143319 @default.
• W2142118082 hasConceptScore W2142118082C3013748606 @default.
• W2142118082 hasConceptScore W2142118082C49105822 @default.
• W2142118082 hasConceptScore W2142118082C54355233 @default.
• W2142118082 hasConceptScore W2142118082C71924100 @default.
• W2142118082 hasConceptScore W2142118082C86803240 @default.
• W2142118082 hasConceptScore W2142118082C90924648 @default.
• W2142118082 hasIssue "6" @default.
• W2142118082 hasLocation W21421180821 @default.
• W2142118082 hasLocation W21421180822 @default.
• W2142118082 hasLocation W21421180823 @default.

• next